1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2024-09, Vol.35, p.S866-S867 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S867 |
|---|---|
| container_issue | |
| container_start_page | S866 |
| container_title | Annals of oncology |
| container_volume | 35 |
| creator | Ciccolini, J. Hamimed, M. Marolleau, S. Perez, C. Benzekry, S. Le Ray, M. Boyer, A. Audigier-Valette, C. Martinez, S. Pegliasco, H. Ray, P. Falchero, L. Serre, A. Cloarec, N. Lebas, L. Hominal, S. Mazieres, J. Pérol, M. Greillier, L. Barlesi, F. |
| description | |
| doi_str_mv | 10.1016/j.annonc.2024.08.1435 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04824878v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753424029545</els_id><sourcerecordid>S0923753424029545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1361-ff70faf283e81f9ef7a447a0075a241e48498d05021639d34c97b7697a20d4693</originalsourceid><addsrcrecordid>eNqFkN1LwzAUxYMoOKd_gpBXwXY3H20SX2TMjw3HNnQ-h6xNWEbXjqYOtr_elqmvPt3LveccOD-EbgnEBEg62MSmLKsyiylQHoOMCWfJGeqRJFWRBE7OUQ8UZZFIGL9EVyFsACBVVPWQI0zCAi_eBosnbEpTHIIPuHJ4Z7eruir88WtrVve49Puq6NZWlGPT2OPvD_sSzz5G0xHemcbbsgkPeLm2eDGZz6x9x03tTXGNLpwpgr35mX30-fK8HI2j6fx1MhpOo4ywlETOCXDGUcmsJE5ZJwznwgCIxFBOLJdcyRwSoCRlKmc8U2IlUiUMhZynivXR3Sl3bQq9q_3W1AddGa_Hw6nubsAl5VLIPWm1yUmb1VUItXV_BgK6A6s3-gRWd2A1SN2BbX2PJ59ti-y9rXXI2t6ZzX1ts0bnlf8n4RsIw4DT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial</title><source>Alma/SFX Local Collection</source><creator>Ciccolini, J. ; Hamimed, M. ; Marolleau, S. ; Perez, C. ; Benzekry, S. ; Le Ray, M. ; Boyer, A. ; Audigier-Valette, C. ; Martinez, S. ; Pegliasco, H. ; Ray, P. ; Falchero, L. ; Serre, A. ; Cloarec, N. ; Lebas, L. ; Hominal, S. ; Mazieres, J. ; Pérol, M. ; Greillier, L. ; Barlesi, F.</creator><creatorcontrib>Ciccolini, J. ; Hamimed, M. ; Marolleau, S. ; Perez, C. ; Benzekry, S. ; Le Ray, M. ; Boyer, A. ; Audigier-Valette, C. ; Martinez, S. ; Pegliasco, H. ; Ray, P. ; Falchero, L. ; Serre, A. ; Cloarec, N. ; Lebas, L. ; Hominal, S. ; Mazieres, J. ; Pérol, M. ; Greillier, L. ; Barlesi, F.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1016/j.annonc.2024.08.1435</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Life Sciences</subject><ispartof>Annals of oncology, 2024-09, Vol.35, p.S866-S867</ispartof><rights>2024</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,310,311,315,781,785,790,791,886,23934,23935,25144,27928,27929</link.rule.ids><backlink>$$Uhttps://inria.hal.science/hal-04824878$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ciccolini, J.</creatorcontrib><creatorcontrib>Hamimed, M.</creatorcontrib><creatorcontrib>Marolleau, S.</creatorcontrib><creatorcontrib>Perez, C.</creatorcontrib><creatorcontrib>Benzekry, S.</creatorcontrib><creatorcontrib>Le Ray, M.</creatorcontrib><creatorcontrib>Boyer, A.</creatorcontrib><creatorcontrib>Audigier-Valette, C.</creatorcontrib><creatorcontrib>Martinez, S.</creatorcontrib><creatorcontrib>Pegliasco, H.</creatorcontrib><creatorcontrib>Ray, P.</creatorcontrib><creatorcontrib>Falchero, L.</creatorcontrib><creatorcontrib>Serre, A.</creatorcontrib><creatorcontrib>Cloarec, N.</creatorcontrib><creatorcontrib>Lebas, L.</creatorcontrib><creatorcontrib>Hominal, S.</creatorcontrib><creatorcontrib>Mazieres, J.</creatorcontrib><creatorcontrib>Pérol, M.</creatorcontrib><creatorcontrib>Greillier, L.</creatorcontrib><creatorcontrib>Barlesi, F.</creatorcontrib><title>1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial</title><title>Annals of oncology</title><subject>Life Sciences</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkN1LwzAUxYMoOKd_gpBXwXY3H20SX2TMjw3HNnQ-h6xNWEbXjqYOtr_elqmvPt3LveccOD-EbgnEBEg62MSmLKsyiylQHoOMCWfJGeqRJFWRBE7OUQ8UZZFIGL9EVyFsACBVVPWQI0zCAi_eBosnbEpTHIIPuHJ4Z7eruir88WtrVve49Puq6NZWlGPT2OPvD_sSzz5G0xHemcbbsgkPeLm2eDGZz6x9x03tTXGNLpwpgr35mX30-fK8HI2j6fx1MhpOo4ywlETOCXDGUcmsJE5ZJwznwgCIxFBOLJdcyRwSoCRlKmc8U2IlUiUMhZynivXR3Sl3bQq9q_3W1AddGa_Hw6nubsAl5VLIPWm1yUmb1VUItXV_BgK6A6s3-gRWd2A1SN2BbX2PJ59ti-y9rXXI2t6ZzX1ts0bnlf8n4RsIw4DT</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Ciccolini, J.</creator><creator>Hamimed, M.</creator><creator>Marolleau, S.</creator><creator>Perez, C.</creator><creator>Benzekry, S.</creator><creator>Le Ray, M.</creator><creator>Boyer, A.</creator><creator>Audigier-Valette, C.</creator><creator>Martinez, S.</creator><creator>Pegliasco, H.</creator><creator>Ray, P.</creator><creator>Falchero, L.</creator><creator>Serre, A.</creator><creator>Cloarec, N.</creator><creator>Lebas, L.</creator><creator>Hominal, S.</creator><creator>Mazieres, J.</creator><creator>Pérol, M.</creator><creator>Greillier, L.</creator><creator>Barlesi, F.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope></search><sort><creationdate>202409</creationdate><title>1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial</title><author>Ciccolini, J. ; Hamimed, M. ; Marolleau, S. ; Perez, C. ; Benzekry, S. ; Le Ray, M. ; Boyer, A. ; Audigier-Valette, C. ; Martinez, S. ; Pegliasco, H. ; Ray, P. ; Falchero, L. ; Serre, A. ; Cloarec, N. ; Lebas, L. ; Hominal, S. ; Mazieres, J. ; Pérol, M. ; Greillier, L. ; Barlesi, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1361-ff70faf283e81f9ef7a447a0075a241e48498d05021639d34c97b7697a20d4693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ciccolini, J.</creatorcontrib><creatorcontrib>Hamimed, M.</creatorcontrib><creatorcontrib>Marolleau, S.</creatorcontrib><creatorcontrib>Perez, C.</creatorcontrib><creatorcontrib>Benzekry, S.</creatorcontrib><creatorcontrib>Le Ray, M.</creatorcontrib><creatorcontrib>Boyer, A.</creatorcontrib><creatorcontrib>Audigier-Valette, C.</creatorcontrib><creatorcontrib>Martinez, S.</creatorcontrib><creatorcontrib>Pegliasco, H.</creatorcontrib><creatorcontrib>Ray, P.</creatorcontrib><creatorcontrib>Falchero, L.</creatorcontrib><creatorcontrib>Serre, A.</creatorcontrib><creatorcontrib>Cloarec, N.</creatorcontrib><creatorcontrib>Lebas, L.</creatorcontrib><creatorcontrib>Hominal, S.</creatorcontrib><creatorcontrib>Mazieres, J.</creatorcontrib><creatorcontrib>Pérol, M.</creatorcontrib><creatorcontrib>Greillier, L.</creatorcontrib><creatorcontrib>Barlesi, F.</creatorcontrib><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ciccolini, J.</au><au>Hamimed, M.</au><au>Marolleau, S.</au><au>Perez, C.</au><au>Benzekry, S.</au><au>Le Ray, M.</au><au>Boyer, A.</au><au>Audigier-Valette, C.</au><au>Martinez, S.</au><au>Pegliasco, H.</au><au>Ray, P.</au><au>Falchero, L.</au><au>Serre, A.</au><au>Cloarec, N.</au><au>Lebas, L.</au><au>Hominal, S.</au><au>Mazieres, J.</au><au>Pérol, M.</au><au>Greillier, L.</au><au>Barlesi, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial</atitle><jtitle>Annals of oncology</jtitle><date>2024-09</date><risdate>2024</risdate><volume>35</volume><spage>S866</spage><epage>S867</epage><pages>S866-S867</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1016/j.annonc.2024.08.1435</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2024-09, Vol.35, p.S866-S867 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04824878v1 |
| source | Alma/SFX Local Collection |
| subjects | Life Sciences |
| title | 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T10%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1380P%20PK/PD%20analysis%20of%20pembrolizumab,%20nivolumab%20and%20atezolizumab%20in%20NSCLC%20patients:%20The%20PIONeeR%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Ciccolini,%20J.&rft.date=2024-09&rft.volume=35&rft.spage=S866&rft.epage=S867&rft.pages=S866-S867&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1016/j.annonc.2024.08.1435&rft_dat=%3Celsevier_hal_p%3ES0923753424029545%3C/elsevier_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753424029545&rfr_iscdi=true |